Multipl Skleroz Hastalığının Engellilik Seviyesine Göre Maliyetleri: Sistematik Derleme Çalışması

Yıl 2021, , 101 - 118, 30.06.2021

Selin Kalender Vahit Yiğit

https://doi.org/10.17827/aktd.876840

Öz

Amaç: Bu çalışma MS hastalarının engellilik seviyeleri ile hastalığın toplam maliyetleri arasındaki ilişkinin ortaya konulmasını amaçlamaktadır. Gereç ve Yöntem: Bu amaçla literatürde hastaların EDSS (Expanded Disability Status Scale) ile belirlenen engellilik seviyelerine göre toplam maliyetlerinin değerlendirildiği hastalık maliyeti (Cost of Illness) çalışmalarının sistematik derlemesi yapılmıştır. Çalışma kapsamında literatür taraması PubMed veri tabanı üzerinde gerçekleştirilmiştir. Çalışmaya Ocak 2000-Aralık 2019 yılları arasında İngilizce olarak yayınlanan, hasta bireyler üzerinde gerçekleştirilen ve doğrudan-dolaylı maliyetlerin hesaplandığı araştırma makaleleri dahil edilmiştir. Tarama 825 yayın ile sonuçlanmıştır. Belirlenen dahil etme kriterleri çerçevesinde maliyetlerin hastaların engellilik seviyelerine göre hesaplandığı 52 çalışma değerlendirme kapsamına alınmış ve sonuçları analiz edilerek karşılaştırılmıştır. Bulgular: Hastalığın toplam maliyetleri (doğrudan+dolaylı) hastaların engellilik seviyelerinin artması ile birlikte (hafif seviye engellilik 26.925 $; orta seviye engellilik 44.429 $; şiddetli seviye engellilik 66.792 $) yükselmektedir. Doğrudan maliyetler içerisinde ilaç tedavi (DMT’ler ve diğer ilaçlar) maliyetleri (%4-%90), dolaylı maliyetler içerisinde ise üretim kayıpları (%3-%68) ana maliyet bileşenini oluşturmaktadır. Sonuç: Çalışmalar arasındaki çeşitli metodolojik farklılıklara rağmen elde edilen sonuçlar, MS’in yükselen maliyetleri nedeniyle önemli ve öncelikli olarak ele alınması gereken bir sağlık sorunu olduğunu ortaya koymaktadır.

Anahtar Kelimeler

Multipl skleroz, hastalık maliyeti, sistematik derleme

Costs of Multiple Sclerosis According to the Level of Disability: A Systematic Review Study

Öz

This study aims to reveal the relationship between the disability levels of MS patients and the total costs of the disease.
For this purpose, a systematic review of Cost of Illness studies on MS in the literature, in which the total costs of
patients are evaluated according to their disability levels determined the EDSS (Expanded Disability Status Scale), has
been performed. Within the scope of the study, the literature search was carried out on the PubMed database. The
study included research articles published in English between January 2000 and December 2019, performed on
sick individuals and calculating direct and indirect costs. The search resulted in 825 publications. 52 studies in which
costs were calculated according to the disability levels of the patients within the framework of the inclusion criteria
were included in the evaluation and their results were analyzed and compared. The total annual costs of the disease
(direct + indirect) increase with the increase in the disability level of the patients (mild disability $ 26,925; moderate
disability $ 44,429; severe disability $ 66,792). Among the direct costs, drugs (Disease modifying drugs and others)
costs (4-90%) and within indirect costs, production losses (3-68%) are the main cost components. Despite the various
methodological differences between the studies, the results obtained reveal that MS is an important and priority
health problem due to its rising costs.

Anahtar Kelimeler

Multiple sclerosis, cost of illness, systematic review

Kaynakça

• 1. Place J. Multipl skleroz ve diğer inflamatuar mss bozuklukları. In The Lancet Nöroloji'de Tedavi El Kitabı (Çeviri Ed Ç Özkara, Ed C Warlow). 1st ed., İstanbul, Elsevier (Sigma Publishing), 2007, p. 201–22.
• 2. Siva A. Merkezi sinir sisteminin demiyelinizan hastalıkları. In Nöroloji Ders Kitabı (Ed H Apaydın). 1st ed., İstanbul, İstanbul Üniversitesi Yayınları, 2009, p. 747–67.
• 3. Costello K. Preface. In Nursing Practice in Multiple Sclerosis: A Core Curriculum (Eds K Costello, J Halper, C Harris). 1st ed., New York, Demos Medical Publishing, 2003, p. v–vi.
• 4. Lynn JD. Multipl skleroz. In Pratik Nöroloji (Çeviri Ed G Şahin, Eds JD Lynn, HB Newton, AD Rae-Grant). Ankara, Güneş Kitabevi, 2005, p. 276–79.
• 5. Ropper AH, Brown RH. Nörolojik hastalıkların ana kategorileri: multipl skleroz ve ilişkili demiyelinizan hastalıklar. In Adam’s and Victor’s Principles of Neurology (Çeviri Ed M Emre) 8th ed., Boston-İstanbul: McGraw Hill-Güneş Kitabevi; 2006, p. 771–96.
• 6. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520–32.
• 7. Ay A. Dokuz Eylül Üniversitesi Hastanesine başvuran multipl skleroz (ms) hastalarında, hastalığa ilişkin tutulum alanlarının yaşam kalitesi üzerine etkisi (Yüksek Lisans Tezi). İzmir, Dokuz Eylül Üniversitesi, 2019.
• 8. Mirza M. Multipl sklerozun etyoloji ve epidemiyolojisi. Erciyes Med J. 2002;24(1):40–7.
• 9. Milo R, Kahana E. Multiple sclerosis: Geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387–94.
• 10. Kolasa K. How much is the cost of multiple sclerosis-systematic literature review. Przegla̧d Epidemiol. 2013;67(1):75–85.
• 11. Casado V, Martínez-Yélamos S, Martínez-Yélamos A, Carmona O, Alonso L, Romero L, et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res. 2006;6(143):1–8.
• 12. Gold R, Toumi M, Meesen B, Fogarty E. The Payer’s Perspective: What is the burden of ms and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? Mult Scler. 2016;22(Suppl 2):60–70.
• 13. Naci H, Fleurence R, Birt J, Duhig A. Economic Burden of multiple sclerosis: A Systematic review of the literature. Pharmacoeconomics. 2010;28(5):363–79.
• 14. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler J. 1998;4(5):419–25.
• 15. Trisolini M, Honeycutt A, Wiener J, Lesesne S. Global Economic Impact of multiple sclerosis literature review executive summary. London, Multiple Sclerosis International Federation 2010.
• 16. Cerqueira JJ, Compston A, Geraldes R, Rosa MM, Schmierer K, Thompson A, et al. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosurg Psychiatry. 2018;89(8):844–50.
• 17. Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–36.
• 18. Patwardhan MB, Matchar DB, Samca GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: A review of literature. Mult Scler. 2005;11(2):232–9.
• 19. Sevim S. Relapses in multiple sclerosis: Definition, pathophysiology, features, imitators, and treatment. Turkish J Neurol. 2016;22(3):99–108.
• 20. Kurtzke JF. Rating neurologic ımpairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.
• 21. Kürtüncü M. EDSS. http://norolojiklinigi.info/edss/ (accessed May 2020).
• 22. Ahmad H, Taylor BV, Van Der Mei I, Colman S, O’Leary BA, Breslin M, et al. The impact of multiple sclerosis severity on health state utility values: Evidence from Australia. Mult Scler. 2017;23(8):1157–66.
• 23. Palmer AJ, Colman S, O’Leary B, Taylor BV, Simmons RD. The economic ımpact of multiple sclerosis in Australia in 2010. Mult Scler J. 2013;19(12):1640–6.
• 24. Palmer AJ, van der Mei I, Taylor B V, Clarke PM, Simpson S, Ahmad H. Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Mult Scler. 2019;2:1–10.
• 25. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;(77):918–26.
• 26. Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - A systematic review. PLoS One. 2016;11(7):1–25.
• 27. Özgülbaş N. Sağlık Sektöründe Hizmet ve Hastalık Maliyet Analizi. 1. Baskı. Ankara, Siyasal Kitabevi, 2014.
• 28. Kobelt G, Berg J, Atherley D, Hadjimichael O, Jönsson B. Costs and quality of life in multiple sclerosis-A cross-sectional study in the USA. 2004. (SSE/EFI Working Paper Series in Economics and Finance). Report No: 594.
• 29. Centre for Epidemiology and Evidence. Commissioning economic evaluations: A guide. Sydney; 2017.
• 30. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.
• 31. Da Silva NL, Takemoto MLS, Damasceno A, Fragoso YD, Finkelsztejn A, Becker J, et al. Cost analysis of multiple sclerosis in Brazil: A cross-sectional multicenter study. BMC Health Serv Res. 2016;16(102):1-12.
• 32. Jones E, Pike J, Marshall T, Ye X. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US. BMC Health Serv Res. 2016;16(102):1-12.
• 33. Bruno D, Marc D, Ouarda P, Dominique S, Marc S, Laurène C, et al. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord. 2019;36(2019):1-8.
• 34. Alowayesh MS, Ahmed SF, Al-Hashel J, Alroughani R. Economic burden of multiple sclerosis on Kuwait health care system. PLoS One.2019;14(5):1–13.
• 35. Coleman CI, Sidovar MF, Roberts MS, Kohn C. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One. 2013;8(1):1-8.
• 36. Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Heal Econ. 2006;7(Suppl 2):S86-95.
• 37. Reese JP, John A, Wienemann G, Wellek A, Sommer N, Tackenberg B, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol. 2011;66(6):311–21.
• 38. Svendsen B, Grytten N, Bø L, Aarseth JH, Smedal T, Myhr KM. The economic impact of multiple sclerosis to the patients and their families in Norway. Eur J Heal Econ. 2018;19(9):1243–57.
• 39. Svendsen B, Myhr KM, Nyland H, Aarseth JH. The cost of multiple sclerosis in Norway. Eur J Heal Econ. 2012;13(1):81–91.
• 40. Jennum P, Wanscher B, Frederiksen J, Kjellberg J. The socioeconomic consequences of multiple sclerosis: A controlled national study. Eur Neuropsychopharmacol. 2012;22(1):36–43.
• 41. McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: Service use, costs, quality of life and disability. Pharmacoeconomics. 2008;26(10):847–60.
• 42. Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in ms study: Results from five european countries. Mult Scler J. 2012;18(2_Suppl):7–15.
• 43. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;(77):918–26.
• 44. Gyllensten H, Wiberg M, Alexanderson K, Friberg E, Hillert J, Tinghög P. Comparing costs of illness of multiple sclerosis in three different years: A population-based study. Mult Scler J. 2018;24(4):520–8.
• 45. Szmurło D, Fundament T, Ziobro M, Kruntorádová K, Doležal T, Głogowski C. Costs of multiple sclerosis-extrapolation of Czech data to Polish patients. Expert Rev Pharmacoeconomics Outcomes Res. 2014;14(3):451–8.
• 46. Chan B, Cadarette S, Wodchis W, Wong J, Mittmann N, Krahn M. Cost-of-illness studies in chronic ulcers: A systematic review. J Wound Care. 2017;26(Suppl 4):S4-14.
• 47. Brodszky V, Beretzky Z, Baji P, Rencz F, Péntek M, Rotar A, et al. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Heal Econ. 2019;20(S1):155–72.
• 48. Larg A, Moss JR. Cost-of-illness studies: A guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71.
• 49. Organisation for Economic Co-operation and Development (OECD). PPPs and exchange rates 2020.https://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4 (accessed Nov 2020).
• 50. The World Bank. PPP conversion factor, GDP (LCU per international $) 2019. https://data.worldbank.org/indicator/PA.NUS.PPP (accessed Nov 2020).
• 51. Kobelt G, Lindgren P, Smala A, Bitsch A, Haupts M, Kölmel HW, et al. Costs and quality of life in multiple sclerosis: An observational study in Germany. Eur J Heal Econ. 2001 Jun;2(2):60–8.
• 52. Kobelt G, Berg J, Lindgren P, Baumhackl U, Berger T, Kolleger H, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Heal Econ. 2006;7(2 Suppl):S14–23.
• 53. Kobelt G, Berg J, Lindgren P, Decoo D, Guillaume D, Neymark N, et al. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Heal Econ. 2006;7(2 suppl.):S24-33.
• 54. Kobelt G, Texier-Richard B, Lindgren P. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult Scler. 2009;15(6):741–51.
• 55. Gracia F, Larreategui M, Rodríguez G, Benzadón A, Ortiz M, Morales D, et al. Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life. PLoS One. 2018;13(10):e0204681.
• 56. Henriksson F, Fredrikson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden. Eur J Neurol. 2001;8(1):27–35.
• 57. Kobelt G, Lindgren P, Parkin D, Francis D, Johnson M, Bates D, et al. Costs and quality of life in multiple sclerosis: A cross-sectional observational study in the UK. Stockholm; 2000. (SSE/EFI Working Paper Series in Economics and Finance).
• 58. Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur J Heal Econ. 2006;7(2 Suppl.):75–85.
• 59. Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Longen PJH, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Heal Econ. 2006;7(2):55–64.
• 60. Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur J Heal Econ. 2006;7:45–54.
• 61. Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Heal Econ. 2006;7(2 Suppl.):S96-104.
• 62. Kobelt G, Berg J, Lindgren P, Berger K, Elias WG, Flachenecker P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Heal Econ. 2006;7(2 Suppl.):S34-44.
• 63. Kobelt G, Berg J, Lindgren P, Izquierdo G, Sánchez-Soliño O, Pérez-Miranda J, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Heal Econ. 2006;7(2):S65–74.
• 64. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis A cross-sectional study in the United States. Neurology. 2006;66:1696–702.
• 65. Gyllensten H, Kavaliunas A, Alexanderson K, Hillert J, Tinghög P, Friberg E. Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Mult Scler J - Exp Transl Clin. 2018 Jul;4(3):205521731878335.
• 66. Blahova-Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: The COMS study. Mult Scler J. 2012;18(5):662–8.
• 67. Taylor B, McDonald E, Fantino B, Sedal L, MacDonnell R, Pittas F, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci. 2007;14(6):532–9.
• 68. Karampampa K, Gustavsson A, Van Munster ETL, Hupperts RMM, Sanders EACM, Mostert J, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: The costs and utilities of MS patients in the Netherlands. J Med Econ. 2013;16(7):939–50.
• 69. Karampampa K, Gustavsson A, Miltenburger C, Neidhardt K, Lang M. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany. Mult Scler. 2012;18(2 Suppl):23–7.
• 70. Karampampa K, Gustavsson A, Miltenburger C, Mora S, Arbizu T. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012;18(2 Suppl):35–9.
• 71. Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler. 2012;18(2 Suppl):29–34.
• 72. Karampampa K, Gustavsson A, Miltenburger C, Tyas D. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Mult Scler. 2012;18(2 Suppl):41–5.
• 73. Johansson E, Gustavsson A, Miltenburger C, Karampampa K, Rumbach L, Rérat K, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France. Mult Scler. 2012;18(2 Suppl):17–22.
• 74. Karabudak R, Karampampa K, Çalışkan Z. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: Results from Turkey. J Med Econ. 2015;18(1):69–75.
• 75. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol. 2012;19(1):e11-25.
• 76. Orlewska E, Mierzejewski P, Zaborski J, Kruszewska J, Wicha W, Fryze W, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol. 2005;12(1):31–9.
• 77. Fogarty E, Walsh C, McGuigan C, Tubridy N, Barry M. Direct and indirect economic consequences of multiple sclerosis in Ireland. Appl Health Econ Health Policy. 2014;12(6):635–45.
• 78. Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany. Mult Scler J. 2017;23(2_Suppl):78–90.
• 79. Berger T, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria. Mult Scler J. 2017 Jun 23;23(2_Suppl):17–28.
• 80. Dubois B, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium. Mult Scler J. 2017;23(2_Suppl):29–40.
• 81. Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Doležal T. New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic. Mult Scler J. 2017;23(2_Suppl):41–52.
• 82. Lebrun-Frenay C, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for France. Mult Scler. 2017;23(2_Suppl):65–77.
• 83. Uitdehaag B, Kobelt G, Berg J, Capsa D, Dalén J. New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands. Mult Scler. 2017;23(2_Suppl):117–29.
• 84. Oreja-Guevara C, Kobelt G, Berg J, Capsa D, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain. Mult Scler J. 2017;23(2_Suppl):166–78.
• 85. Brundin L, Kobelt G, Berg J, Capsa D, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden. Mult Scler J. 2017;23(2_Suppl):179–91.
• 86. Calabrese P, Kobelt G, Berg J, Capsa D, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland. Mult Scler J. 2017;23(2_Suppl):192–203.
• 87. Battaglia M, Kobelt G, Ponzio M, Berg J, Capsa D, Dalén J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scler J. 2017;23(2_Suppl):104–16.
• 88. Péntek M, Kobelt G, Berg J, Capsa D, Dalén J, Bíró Z, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary. Mult Scler J. 2017;23(2_Suppl):91–103.
• 89. Sá MJ, Kobelt G, Berg J, Capsa D, Dalén J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal. Mult Scler J. 2017;23(2_Suppl):143–54.
• 90. Rasmussen PV, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark. Mult Scler J. 2017;23(2_Suppl):53–64.
• 91. Selmaj K, Kobelt G, Berg J, Orlewska E, Capsa D, Dalén J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland. Mult Scler J. 2017;23(2_Suppl):130–42.
• 92. Boyko A, Kobelt G, Berg J, Boyko O, Popova E, Capsa D, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. Mult Scler J. 2017;23(2_Suppl):155–65.
• 93. Thompson A, Kobelt G, Berg J, Capsa D, Eriksson J, Miller D. New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. Mult Scler J. 2017;23(2_suppl):204–16.
• 94. Sicras-Mainar A, Ruíz-Beato E, Navarro-Artieda R, Maurino J. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res. 2017;17(854):1–7.
• 95. Amato MP, Battaglia MA, Caputo D, Fattore G, Gerzeli S, Pitaro M, et al. The costs of multiple sclerosis: A cross-sectional, multicenter cost-of-illness study in Italy. J Neurol. 2002;249(2):152–63.
• 96. Ponzio M, Gerzeli S, Brichetto G, Bezzini D, Mancardi GL, Zaratin P, et al. Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurol Sci. 2015;36(2):227–34.
• 97. Carney P, O’Boyle D, Larkin A, McGuigan C, O’Rourke K. Societal costs of multiple sclerosis in Ireland. J Med Econ 2018;21(5):425–37.
• 98. Ruutiainen J, Viita AM, Hahl J, Sundell J, Nissinen H. Burden of illness in multiple sclerosis (DEFENSE) study: The costs and quality-of-life of Finnish patients with multiple sclerosis. J Med Econ. 2016 Jan 2;19(1):21–33.
• 99. Torabipour A, Asl ZA, Majdinasab N, Ghasemzadeh R, Tabesh H, Arab M. A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in Khuzestan, Iran. Int J Prev Med. 2014;5(9):1131–8.
• 100. Ysrraelit C, Caceres F, Villa A, Marcilla MP, Blanche J, Burgos M, et al. ENCOMS: Encuesta argentina sobre costos de la enfermedad y necesidades no cubiertas en pacientes con esclerosis múltiple. Arq Neuropsiquiatr. 2014;72(5):337–43.
• 101. Kobelt G, Eriksson J, Phillips G, Berg J. The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms. Mult Scler J. 2017;(2_Suppl):4–16.
• 102. European Central Bank. Determination of the euro conversion rates 1998. https://www.ecb.europa.eu/press/pr/date/1998/html/pr981231_2.en.html (accessed Nov 2020).
• 103. Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study. Neurology. 2011;77(4):355–63.
• 104. Orlewska E. Economic burden of multiple sclerosis: What can we learn from cost-of-illness studies? Expert Rev Pharmacoeconomics Outcomes Res. 2006;6(2):145–54.
• 105. Yamamoto D, Campbell JD. Cost-effectiveness of multiple sclerosis disease-modifying therapies: A systematic review of the literature. Autoimmune Dis. 2012;1(1):1–13.
• 106. Tinelli M, Kanavos P, Efthymiadou O, Visintin E, Grimaccia F, Mossman J. Using IMPrESS to guide policy change in multiple sclerosis. Mult Scler J. 2018;24(9):1251–5.